Who
Matthew K. Fust
Director
Company insider
Files Form 4 as: Director, Crinetics Pharmaceuticals; Director, Atara Biotherapeutics; Director, Neumora Therapeutics; Director, Ultragenyx Pharmaceutical; Director, Dermira; Director, MacroGenics; EVP & Chief Financial Officer, Onyx Pharmaceuticals; EVP, Chief Financial Officer, Jazz Pharmaceuticals.
In numbers
- Trades disclosed
- 294
- Buys
- 2
- Sells
- 40
- Bought
- $206K
- Sold
- $15.2M
- Companies
- 8
- Companies where not an officer
- 6
- First trade
- 6 Jun 2007
- Last trade
- 1 Sep 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $1.9M22,836 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $504K5,925 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $174K2,092 at $83.09 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $174K2,092 at $83.09 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.1M17,500 at $64.68 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $504K12,500 at $40.29 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $545K10,350 at $52.67 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $478K9,730 at $49.13 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.1M17,500 at $64.68 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $504K12,500 at $40.29 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $545K10,350 at $52.67 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $478K9,730 at $49.13 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $1.9M22,836 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $504K5,925 at $85.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —5,925 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,730 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,730 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —5,925 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
News
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid TumorsMGNX · manilatimes.net · 15 Oct 2026Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)RARE · themarketsdaily.com · 15 Oct 2026Ultragenyx (NASDAQ: RARE) agrees to sell PRV for $203 million in cashRARE · tickerreport.com · 14 Oct 2026Head-To-Head Contrast: Zenas BioPharma (NASDAQ:ZBIO) and MacroGenics (NASDAQ:MGNX)MGNX · themarketsdaily.com · 14 Oct 2026MacroGenics (NASDAQ:MGNX) vs. Keros Therapeutics (NASDAQ:KROS) Head to Head ReviewMGNX · tickerreport.com · 7 Oct 2026
0 headlines in the last 90 days name Matthew K. Fust; 5 articles from the last 14 days about the 4 companies they traded most, at most three about any one of them.